Summary
The pharmacokinetics of cisplatin in mice with s. c. RIF 1 tumours was studied after intratumoural (i.t.) administration of drug in solution and in different slow-release devices. The data were compared with those obtained after i.p. administration of cisplatin. The slow-release devices under test were manufactured from either starch (ST) or polymeric hydrogels with different water uptakes (named T1, T2 and T3). In vitro release from these devices was approximately 100% in 2 h for starch rods, 100% in 24h for T3 hydrogels, 45% in 4 days for T2 hydrogels and <10% in 4 days for T1 hydrogels. In vivo release rates agreed well with the in vitro data for T1 and T2 rods and were slightly slower in vivo for the T3 rods. The ST rods released the drug 6 times slower in vivo than in vitro. Plasma concentrations after i. t. administration were lower than those measured after i.p. administration. Systemic exposure to both total and free platinum was reduced to 70% for i.t. as compared with i. p. administration. Tumour concentrations were 4 times higher after i. t. than after i. p. administration. Tumour and peak plasma levels of platinum increased with increasing release rates. With the faster-releasing formulations (ST and T3), tumour platinum concentrations were 100 times higher than after i.p. administration. With the slower releasing formulations (T1 and T2), total tumour platinum concentrations were 2 and 9 times higher, respectively, than after i. t. administration of cisplatin in solution. Platinum distribution within the tumour was homogeneous after i. p. administration. After i. t. administration of cisplatin in solution, platinum concentrations in the centre of the tumour were approximately 4 times higher than in peripheral tumour tissue. Implantation of cisplatin in T2 and T3 hydrogel rods resulted in large concentrations of platinum in the centre of the tumour (the site of implant), which decreased steeply towards the tumour periphery. In summary, i. t. administration of cisplatin solution produced better results than did systemic (i. p.) administration in terms of tumour versus plasma drug-concentration ratios. Administration of drug in slowrelease rods proved even more advantageous, although this was offset by inhomogeneous drug distributions within the tumour.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amano T, Prout GR, Lin C-W (1988) Intratumor injection as a more effective means of porphyrin administration for photodynamic therapy. J Urol 139:392
Begg AC, Bartelink H, Stewart FA, Brown DM, Luck EE (1988) Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system. NCI Monogr 6: 133
Bier J, Benders P, Wenzel M, Bitter K (1979) Kinetics of [57Co]-bleomycin in mice after intravenous, subcutaneous and intratumoral injection. Cancer 44: 1194
Deurloo MJM, Bohlken S, Kop W, Hennink W, Lerk CF, Bartelink H, Begg AC (1990) Intratumoral administration of cisplatin in slow-release devices: I. Tumour response and animal toxicity. Cancer Chemother Pharmacol (in press)
Gibaldi M, Perrier D (1982) Pharmacokinetics. Drugs and the pharmaceutical sciences. Marcel Dekker, New York Basel
Hecquet B, Fournier C, Depadt G, Cappelaere P (1986) Preparation and release kinetics of microencapsulated cisplatin with ethylcellulose. J Pharm Pharmacol 36: 803
Hecquet B, Chabot F, Delatorre Gonzalez JC, Founier C, Hilali S, Cambier L, Depadt G, Vert M (1986) In vivo sustained release of cisplatin from bioresorbable implants in mice. Anticancer Res 6: 1251
Kaetsu I, Yoshida M, Asano M, Yamanaka H, Imai K, Yuasa H, Mashimo T, Suzuki K, Katakai R, Oya M (1987) Biodegradable implant composites for local therapy. J Controlled Release 6:249
Kostron H, Bellnier DA, Lin C-W, Swartz MR, Martuza RL (1986) Distribution, retention, and phototoxicity of hematoporphyrin derivative in a rat glioma. J Neurosurg 64: 768
Kroin JS, Penn RD (1982) Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10: 349
Letner C (ed) (1982) Geigy scientific tables, vol 2. Ciba-Geigy, Basle
Los G, Mutsaers PHM, Vijgh WJF van der, Baldew GS, Graaf PW de, McVie GJ (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380
Los G, Mutsaers PHM, Lenglet WJM, Baldew GS, McVie JG (1989) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389
Morrison PF, Dedrick RL (1986) Transport of cisplatin in rat brain following microinfusion. J Pharm Sci 75: 120
Nagase M, Nomura T, Nakajima T (1987) Effects of intralesional versus IP administration of cisplatin on squamous cell carcinoma in mice. Cancer Treat Rep 71: 825
Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA, Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion ofcis-diamminedichloroplatinum(II) in man. Cancer Treat Rep 62: 1359
Pedley DG, Skelly PJ, Tighe BJ (1980) Hydrogels in biomedical applications. Br Polym J 12: 99
Spenlehauer G, Vert M, Benoit J-P, Chabot F, Veillard M (1988) Biodegradable cisplatin microspheres prepared by the solvent evaporation method: morphology and release characteristics. J Controlled Release 7:217
Takahashi H, Nakazawa S, Shimura T (1985) Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 62: 120
Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF (1980) A new mouse tumor model system (RIF-1) for comparison of endpoint studies. J Natl Cancer Inst 64: 595
Vermorken JB, Van Der Vijgh WJF, Klein I, Gall HE, Van Groningen CJ, Hart GHM, Pinedo HM (1986) Pharmacokinetics of free and total cisplatin species after rapid and prolonged infusion of cisplatin. Clin Pharmacol Ther 39: 136
Wenzel M, Schneider M, Bier J, Benders P, Schachschneider G (1979) Concentrations of cytostatic drugs in organs and tumors: comparison after intravenous and intratumoral injection. J Cancer Res Clin Oncol 95: 147
Wenzel M, Schneider M, Bier J (1980) Toxicity and cytostatic effect of PtCl2(NH3)2 after i. v. and i. t. injection. Z Naturforsch 35c: 838
Yu NY, Conley FK, Luck EE, Brown DM (1988) Response of murine tumors to matrix associated cisplatin intratumoral implants. NCI Monogr 6: 137
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deurloo, M.J.M., Kop, W., van Tellingen, O. et al. Intratumoural administration of cisplatin in slow-release devices: II. pharmacokinetics and intratumoural distribution. Cancer Chemother. Pharmacol. 27, 347–353 (1991). https://doi.org/10.1007/BF00688856
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00688856